OPHTHETIC
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
Jan 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 15h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPHTHETIC is a small-molecule ophthalmic solution approved in 1961 for eye care indications. The exact therapeutic mechanism and indications are not publicly detailed in available data. This is a legacy NDA product with a long commercial history in ophthalmology.
LOE Approaching
As LOE approaches, the brand team will likely shift focus to lifecycle extension strategies, generic defense, or transition planning; expect smaller or consolidating commercial teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on OPHTHETIC offers experience in mature-market management, generic defense, and lifecycle extension strategy—valuable skills in a consolidating market. However, LOE approaching indicates declining headcount and career growth; best suited for professionals seeking stability in a legacy brand or transitioning to other roles within AbbVie.
Brand ManagerMedical Science Liaison
Worked on OPHTHETIC at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.